Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

The goal of this phase 2 clinical trial is to learn if patients with Multiple Myeloma who are minimal residual disease positive after initial therapy (including an autologous stem cell transplant \[ASCT\]) will benefit from maintenance therapy with Iberdomide and subcutaneous (SC) Daratumumab. The main questions it aims to answer are: * Assess if giving Iberdomide and the SC Daratumumab in the maintenance setting is an effective treatment and warrants further investigation in patients with residual disease * Is giving Iberdomide and SC Daratumumab maintenance post ASCT a safe option Particip

Trial Details

NCT ID
NCT06107738
Phase
PHASE2
Sponsor
Barbara Ann Karmanos Cancer Institute
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Iberdomide
  • Daratumumab/rHuPH20 Co-formulation
Locations (sample)
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Lansing, Michigan, United States|42.73253,-84.55553

Key Eligibility Criteria

  • Multiple Myeloma patients who have received prior DARA-containing induction therapy and have attained at least a partial response.
  • Patients who have completed Autologous Stem Cell Transplant (ASCT) 90-150 days prior to registration, without any post-ASCT therapy and without pos…
  • Patients who are Minimal Residual Disease positive (MRD (+)) as measured by the ClonoSEQ assay using a sensitivity of 10-5, measured 90-150 days fo…
  • Prior DARA-containing induction therapy (at least 3 cycles), attaining at least a partial response.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →